Female Health Co. (NASDAQ:FHCO)
The Female Health Company engages in the manufacture, marketing, and distribution of the female condom.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
TMFTheDoctor
(80.45)
Submitted: 4/5/2012 3:52:34 PM :
Start Price:
$5.26
FHCO Score:
+18.31
http://www.fool.com/investing/general/2012/03/17/the-stock-that-could-make-a-fortune-saving-lives.aspx
Recs
ckoerber9
(63.02)
Submitted: 3/19/2012 9:49:06 AM :
Start Price:
$5.27
FHCO Score:
+17.88
Having a daughter makes this an easy pick. I want her to be able to be safe and and not rely on a guy to 'protect' himself. FHCO currently appears to be on the right track and if it stays on this path I see the stock doubling in 5 years.
Recs
ewamlb
(61.83)
Submitted: 2/13/2012 10:05:54 PM :
Start Price:
$5.12
FHCO Score:
+17.38
Female contraception, what more do I have to say.......
Recs
thajny
(< 20)
Submitted: 5/6/2011 4:09:43 PM :
Start Price:
$4.56
FHCO Score:
+31.06
The Management of the company is top-notch with a no-debt balance sheet and people who believe in the mission. There is no games playing.
Recs
familyfund2
(21.86)
Submitted: 2/27/2011 1:15:36 PM :
Start Price:
$4.97
FHCO Score:
+19.16
http://caps.fool.com/Blogs/high-yields-from-nasdaq-100-as/546142
Recs
steprightup
(76.31)
Submitted: 1/21/2011 1:21:40 PM :
Start Price:
$5.08
FHCO Score:
+13.32
Simply curious as to how this plays out. Used the google screener and utilized the return on investment and return on equity; compunded revenue 5 yrs. and 10 yrs.
41% roi and 44% roe; 15% 5 and 10 yrs. compounded anually. Easy to consider equity valuations to double over the next five years as well as sales.
Expected compounded pre-tax returns would range approxiamately 6 to 12 percent a year.
Recs
jquinn60137
(66.73)
Submitted: 1/8/2011 2:27:09 PM :
Start Price:
$5.42
FHCO Score:
-4.52
The foolish flow on this stock seems way too high. I worry about a cash crunch down the line.
Recs
Epi315
(94.79)
Submitted: 11/9/2010 9:30:06 AM :
Start Price:
$6.14
FHCO Score:
-11.68
Risky pick that depends heavily on the acceptance of the female condom in the global market - notably Africa. In the short term, with this President--who supports this form of female empowerment--USAID may be given enough of a green-light to virtually single-handedly buoy sales and distribution of the female condom throughout developing countries (most notably in SSA). How sustainable that is for the long-run is anyone's guess.
Recs
Hopel3ss
(65.13)
Submitted: 11/4/2010 7:32:31 PM :
Start Price:
$5.79
FHCO Score:
-6.00
Growth market, nice dividend, and no debt but P/E and P/S a little high. Nice stock to watch.
Recs
zackjcooper
(24.29)
Submitted: 11/4/2010 3:44:38 PM :
Start Price:
$5.74
FHCO Score:
-5.37
They own the market. As described in the SEC report, there are only two competitors in the female condom market and neither contain FDA approval.
Recs
roolbreakers
(< 20)
Submitted: 11/4/2010 12:05:06 PM :
Start Price:
$5.70
FHCO Score:
-5.05
global gains
Recs
baskins
(< 20)
Submitted: 10/19/2010 7:56:40 PM :
Start Price:
$5.50
FHCO Score:
-5.70
I just watched the usage video for this product on FHCO's website. I just do not see it being practical when in comparison to traditional condoms. However with the strong balance sheet, I feel some may suck up these shares cheap, driving the price up. Couple that with the international trend of contraceptives growing at fast rates, especially in less established countries, this could become the norm just like the male condom did here in the states. For those reason, I give an outperform
Recs
vanzweb
(< 20)
Submitted: 10/11/2010 5:17:39 PM :
Start Price:
$4.81
FHCO Score:
-9.03
Unless they add new products I don't see a demand for this product. Regular condoms, pills and injections is the norm, much more convienent. This product doesn't address current conusmers needs. Just another novelty. Growth is looking slim.
Recs
russkr
(< 20)
Submitted: 9/15/2010 10:48:11 AM :
Start Price:
$4.47
FHCO Score:
+14.59
Strong balance sheet, debt free and creating an innovative and important product. Bonus: good dividend.
Recs
Seafairer
(49.64)
Submitted: 9/1/2010 9:18:02 AM :
Start Price:
$4.49
FHCO Score:
+7.52
FDA approved medical device for women, very low debt, positive earnings!
Recs
Ax7777
(< 20)
Submitted: 8/23/2010 8:27:38 PM :
Start Price:
$4.38
FHCO Score:
+9.97
Sales should increase, driving profitability.
Recs
mat05
(< 20)
Submitted: 8/13/2010 10:34:14 AM :
Start Price:
$4.34
FHCO Score:
+14.52
growth speculative play
Recs
DesireDemon
(27.50)
Submitted: 7/18/2010 2:05:48 PM :
Start Price:
$4.67
FHCO Score:
+2.53
Female Health Company owns worldwide rights to the female condom.
It is the only FDA approved female condom. So currently they have no competition.
Revenue growth of 36% from 2007 to 2008 & 7% growth from 2008 to 2009.
Healthy balance sheet, paltry debt, 4% dividend, has increased EPS every year.
The management seems interested in increasing shareholder value.
As of July 18th I own 1,000 shares of FHCO @ $5.07 per share. I will continue to add to my position.
This company a US based company located in Chicago, IL.
Other thoughts: The company currently has a daily volume of 55,000 shares. FHCO has no stock analyst following the company, although this could change in time.
Recs
bodie17
(< 20)
Submitted: 7/18/2010 8:34:12 AM :
Start Price:
$4.65
FHCO Score:
+3.39
Women take charge of their health, etc.
Recs
KamsterJas
(21.74)
Submitted: 7/18/2010 6:07:31 AM :
Start Price:
$4.65
FHCO Score:
-3.39
Despite of Female Health Corporation's oozing potential (as some Fools mentioned) in creating a demand that appears lucrative, ethical, and everlasting, I decide to take the opposite side here and state that FHCO is unlikely to outperform the market in the coming years based on the following reasons:
1. Business strategy ignores the retail sector: FHCO’s business is strictly focused on gaining government and UN contracts; while there is no problem doing so, it should be noted that the retail side has been largely ignored in many potential markets. It appears that the management team is satisfied with this strategy and takes no initiative in selling its products to retail customers and makes the company vulnerable to substantial profitability risks when the governments back out.
2. Stick-in-the-mud vision: Mr. O.B.Parrish has a noble pursuit in stopping the STD around the world, and I, like many others, commence him for the dedicated effort for the past 10 years. The recent cut-back on research and development and marketing campaign, however, indicates that the management team appears to be satisfied with what they already have. Correct me if I am wrong, but I think at this stage, the company should focus even more on raising more awareness, developing safer and more appealing products, and diversifying into different markets. How otherwise can the company fight off competition when a large corp, say Durex, sees the potential and enters?
3. Vague clarifications in the company’s strength: This one deserves more research. For a manufacturer of consumer products, a few factors are key to its success: Manufacturing efficiency, logistics efficiency, labor relations, warehousing policy, marketing campaigns, and sustainable pipelines. I do not see the company disclosing anything about how it is superior, or perhaps someone can show me.
4. Options and Preferred shares shenanigans: To be honest, I just don’t understand how the reward structure in FHCO works, the company’s stock option plans and preferred share structure confuses the hell out of me; combine that with the newly initiated dividend and constant stock buy-backs, I cannot help but become suspicious of the management’s intention: are they filling their own pockets with the company’s cash?
5. Sky-high evaluation: currently FHCO is trading at 11x P/B, 35x P/E, and 42 P/FCF. Given that the reward of government contract is highly unpredictable and the possibly of competition, I personally believe that this evaluation is not sustainable.
In light of such believes, I will perhaps get in touch with the management after the next conference call to dig deeper and hopefully resolve these questions; before that, no long positions will be initiated (unless the stock drops to $1-2, ha)
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 41 : 1 2 3 Next »